Last reviewed · How we verify

traditional triple antihypertensive treatment

First Affiliated Hospital of Chengdu Medical College · Phase 3 active Small molecule

traditional triple antihypertensive treatment is a Antihypertensive combination therapy Small molecule drug developed by First Affiliated Hospital of Chengdu Medical College. It is currently in Phase 3 development for Hypertension (resistant or difficult-to-control).

Traditional triple antihypertensive treatment combines three different classes of blood pressure-lowering agents to reduce systemic vascular resistance and blood pressure through complementary mechanisms.

The traditional triple antihypertensive treatment, developed by the First Affiliated Hospital of Chengdu Medical College, is under investigation for resistant hypertension. Current trials focus on novel interventional techniques, including adrenal artery ablation and embolization, aiming to address uncontrolled hypertension. Despite no FDA label, the treatment shows promise in early-phase studies.

At a glance

Generic nametraditional triple antihypertensive treatment
SponsorFirst Affiliated Hospital of Chengdu Medical College
Drug classAntihypertensive combination therapy
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

This combination typically includes agents from different drug classes (such as ACE inhibitors/ARBs, calcium channel blockers, and diuretics or beta-blockers) that work synergistically to lower blood pressure via distinct pathways: reducing renin-angiotensin system activity, blocking calcium influx in vascular smooth muscle, and promoting sodium/fluid excretion or reducing cardiac output. The multi-mechanism approach allows for more effective blood pressure control with potentially lower doses of individual agents.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about traditional triple antihypertensive treatment

What is traditional triple antihypertensive treatment?

traditional triple antihypertensive treatment is a Antihypertensive combination therapy drug developed by First Affiliated Hospital of Chengdu Medical College, indicated for Hypertension (resistant or difficult-to-control).

How does traditional triple antihypertensive treatment work?

Traditional triple antihypertensive treatment combines three different classes of blood pressure-lowering agents to reduce systemic vascular resistance and blood pressure through complementary mechanisms.

What is traditional triple antihypertensive treatment used for?

traditional triple antihypertensive treatment is indicated for Hypertension (resistant or difficult-to-control).

Who makes traditional triple antihypertensive treatment?

traditional triple antihypertensive treatment is developed by First Affiliated Hospital of Chengdu Medical College (see full First Affiliated Hospital of Chengdu Medical College pipeline at /company/first-affiliated-hospital-of-chengdu-medical-college).

What drug class is traditional triple antihypertensive treatment in?

traditional triple antihypertensive treatment belongs to the Antihypertensive combination therapy class. See all Antihypertensive combination therapy drugs at /class/antihypertensive-combination-therapy.

What development phase is traditional triple antihypertensive treatment in?

traditional triple antihypertensive treatment is in Phase 3.

What are the side effects of traditional triple antihypertensive treatment?

Common side effects of traditional triple antihypertensive treatment include Hypotension, Dizziness, Electrolyte abnormalities, Cough (if ACE inhibitor component), Peripheral edema (if calcium channel blocker component).

Related